Published in
Impact Journals, Oncotarget, 8(9), p. 7859-7866, 2017
DOI: 10.18632/oncotarget.23559
Links
Tools
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
Journal article published in 2017 by
Chiara Cremolini 
,
Marzia Del Re ,
Carlotta Antoniotti,
Sara Lonardi,
Francesca Bergamo,
Fotios Loupakis,
Beatrice Borelli,
Federica Marmorino,
Valentina Citi,
Enrico Cortesi,
Roberto Moretto,
Monica Ronzoni,
Gianluca Tomasello,
Alberto Zaniboni,
Patrizia Racca
and other authors.
,
Marzia Del Re ,
Carlotta Antoniotti,
Sara Lonardi,
Francesca Bergamo,
Fotios Loupakis,
Beatrice Borelli,
Federica Marmorino,
Valentina Citi,
Enrico Cortesi,
Roberto Moretto,
Monica Ronzoni,
Gianluca Tomasello,
Alberto Zaniboni,
Patrizia Racca
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 